Overview
- Editors:
-
-
Beverly A. Teicher
-
Dana-Farber Cancer Institute, Boston, USA
Access this book
Other ways to access
Table of contents (16 chapters)
-
-
In Vitro Methods
-
-
-
-
- Axel-R. Hanauske, Susan G. Hilsenbeck, Daniel D. Von Hoff
Pages 43-56
-
In Vivo Methods
-
-
-
- Thomas Corbett, Fred Valeriote, Patricia LoRusso, Lisa Polin, Chiab Panchapor, Susan Pugh et al.
Pages 75-99
-
- Jacqueline Plowman, Donald J. Dykes, Melinda Hollingshead, Linda Simpson-Herren, Michael C. Alley
Pages 101-125
-
-
-
-
- David M. Vail, E. Gregory MacEwen
Pages 197-213
-
Clinical Testing
-
Front Matter
Pages 215-215
-
-
-
- Christine Khater, Paul Laub, James M. Gallo, André Rogatko, Peter J. O’Dwyer
Pages 249-270
-
- Thomas Anthony Connors, Herbert M. Pinedo
Pages 271-288
-
-
About this book
Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe the arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.
Reviews
"Authoritative and up-to-date...takes oncologists, pharmacologists, medicinal chemists and other cancer researchers on an encyclopedic tour of the cancer drug development and approval process, moving from the design and execution of high throughput screens, to preclinical testing under FDA requirements, to early clinical trials, and on to final FDA approval." - Tumori
Editors and Affiliations
-
Dana-Farber Cancer Institute, Boston, USA
Beverly A. Teicher